Immunogenicity, reactogenicity, and safety of an mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine, mRNA-1083, in adults aged ≥50 years in Japan
Hiroyuki Fukase, Alexander Rumyantsev, Osamu Kogawara,Koichi Hashizume, Seun Osibajo, Lusine Kostanyan
This oral presentation was presented at ESCMID 2026 which was held in Munich, Germany from 17-21 April, 2026. This page will not be available beyond 30 days after the congress has closed.